期刊文献+

乳腺癌化疗敏感性与药物遗传学分子标志物相关性研究

原文传递
导出
摘要 目的:综述乳腺癌化疗敏感性与药物遗传学分子标志物相关性的研究进展。方法:以药物遗传学、分子标志物、乳腺癌等为关键词检索Medline收录的相关文献,并对其进行整理和分析。结果:乳腺癌化疗敏感性相关药物遗传学分子标志物包括胸苷酸合成酶(thymidylate synthase,TS)、胸苷磷酸化酶(thymidine phosphorylase,TP)、人表皮生长因子受体2(human epidermalgrowth factor receptor2,Her-2/neu)、谷胱甘肽-S-转移酶(glutathione S-transferase,GSTs)等。结论:乳腺癌化疗相关药物遗传学分子标志物研究的广泛深入为基于药物遗传学的乳腺癌个体化治疗提供了可能。
出处 《中国药房》 CAS CSCD 北大核心 2011年第14期1324-1326,共3页 China Pharmacy
  • 相关文献

参考文献15

  • 1S. B. Fox,K. Engels,M. Comley,R. M. Whitehouse,H. Turley,K. C. Gatter,A. L. Harris.Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF[J]. Annals of Oncology . 1997 (3)
  • 2Bergqvist J,,Ohd JF,Smeds J,et al.Quantitative real-time PCR analysis and microarray-based RNA expression of HER2in relation to outcome. Annals of Oncology . 2007
  • 3Montemurro F,Donadio M,Clavarezza M,et al.Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. The Oncologist . 2006
  • 4Sweeney C,Ambrosone CB,Joseph L,et al.Associationbetween a glutathione S-transferase A1promoter polymor-phism and survival after breast cancer treatment. International Journal of Cancer . 2003
  • 5Nagaoka H,lino Y,Takei H,et al.platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in macrophages correlates with tumor angiogenesis and prognosis in invasive breast cancer. International Journal of Oncology . 1998
  • 6Pritchard K I,Shepherd LE,O’Malley FP,et al.HER2 and responsiveness of breast cancer to adjuvant chemotherapy. New England Journal of Medicine, The . 2006
  • 7Aschele C,Debernardis D,Bandelloni R, et al.Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. Annals of Oncology . 2002
  • 8J Honda,M Sasa,T Moriya,Y Bando,T Hirose,M Takahashi.Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results. Journal of Medical Investigation . 2008
  • 9Yamashita H,Toyama T,Nishio M,et al.p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Research . 2006
  • 10Papaldo,P,Fabi,A,Ferretti,G.A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Annals of Oncology . 2006

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部